The study is headed by Eduard Batlle, coordinator of the Oncology Programme at IRB Barcelona and ICREA Research Professor.

The organization of tissues and organs in the human body can be compared to a very complex and sophisticated engine, whose structure is maintained by positioning its components (cells) in a very precise way. Errors in the assembly (location) of the components might lead to changes in the function of the engine (tissue or organ).

Complex tissues and organs require the separation of diverse cells types into separate zones in order to maintain their architecture. In the case of the intestinal epithelium, the lower part of the invaginations formed by the epithelium, called crypts, contains stem cells that regenerate tissue, while the upper part holds differentiated cells that are responsible for nutrient absorption.

The so-called EphB receptors, present in the cells at the bottom of the crypts, bind to Ephrin ligands located mainly in differentiated cells in the upper part of the intestinal epithelium. The ligand-receptor binding occurs at the frontier between the two cell populations and controls cell positioning in the tissue. However, until now, the way in which these ligand-receptor bindings instruct cells to position themselves in one place or another was unknown.

The results of this study demonstrate that EphB-ephrin bindings activate the metaloprotease ADAM10, which destroys the binding between distinct cell types, such as between cells from the bottom and surface of crypts. It is the destruction of these binding between cells from distinct compartments that prevents cell mixing, thus impeding once cell type from entering the wrong territory.

In the words of Guiomar Solanas, first author of the article, "we have found the molecular mechanisms by which EphB receptors and their ligands tell each cell where it has to be throughout its life: from its generation from stem cells in the crypt bottom until its differentiation". The loss of cell organization in a tissue is often associated with cancer